Brett A. Grimaud's most recent trade in Theravance Biopharma Inc was a trade of 75,000 Ordinary Shares done . Disclosure was reported to the exchange on Feb. 28, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Theravance Biopharma Inc | Brett A. Grimaud | SVP, GEN COUNSEL AND SECRETARY | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 75,000 | 393,811 (0%) | 0% | 0 | Ordinary Shares | |
Theravance Biopharma Inc | Brett A. Grimaud | SVP, GEN COUNSEL AND SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.66 per share. | 20 Feb 2025 | 14,534 | 318,811 (0%) | 0% | 9.7 | 140,398 | Ordinary Shares |
Theravance Biopharma Inc | Brett A. Grimaud | SVP, GEN COUNSEL AND SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.97 per share. | 20 Nov 2024 | 9,268 | 333,345 (0%) | 0% | 10.0 | 92,402 | Ordinary Shares |
Theravance Biopharma Inc | Brett A. Grimaud | SVP, GEN COUNSEL AND SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.22 per share. | 20 Aug 2024 | 9,268 | 342,613 (0%) | 0% | 8.2 | 76,183 | Ordinary Shares |
Theravance Biopharma Inc | Brett A. Grimaud | SVP, GEN COUNSEL AND SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.10 per share. | 20 May 2024 | 9,268 | 351,881 (0%) | 0% | 9.1 | 84,339 | Ordinary Shares |
Theravance Biopharma Inc | Brett A. Grimaud | SVP, GEN COUNSEL AND SECRETARY | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 100,000 | 360,684 (0%) | 0% | 0 | Ordinary Shares | |
Theravance Biopharma Inc | Brett A. Grimaud | SVP, GEN COUNSEL AND SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.92 per share. | 20 Feb 2024 | 17,595 | 260,684 (0%) | 0% | 8.9 | 156,947 | Ordinary Shares |
Theravance Biopharma Inc | Brett A. Grimaud | SVP, GEN COUNSEL AND SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.70 per share. | 20 Aug 2023 | 8,912 | 285,297 (0%) | 0% | 9.7 | 86,446 | Ordinary Shares |
Theravance Biopharma Inc | Brett A. Grimaud | SVP, GEN COUNSEL AND SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.21 per share. | 20 May 2023 | 11,469 | 294,209 (0%) | 0% | 11.2 | 128,567 | Ordinary Shares |
Theravance Biopharma Inc | Brett A. Grimaud | SVP, GEN COUNSEL AND SECRETARY | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 75,000 | 304,958 (0%) | 0% | 0 | Ordinary Shares | |
Theravance Biopharma Inc | Brett A. Grimaud | SVP, GEN COUNSEL AND SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.44 per share. | 20 Feb 2023 | 10,198 | 229,958 (0%) | 0% | 10.4 | 106,467 | Ordinary Shares |